BPC-157 + TB-500 Blend
The "wolverine stack" that pairs BPC-157 and TB-500 in one vial for complementary tissue-repair pathways, backed by strong component preclinical data but zero controlled trials on the blend itself.
The BPC-157 + TB-500 blend combines the two most-used healing peptides in a single formulation, marketed for tissue repair and injury recovery. BPC-157 contributes angiogenesis, nitric oxide signaling and local growth-factor effects, while the TB-500 component contributes actin regulation and cell migration, so on paper the two cover different ground. The mechanistic rationale is coherent and community reports around tendinopathies are persistent, but no controlled human study has shown that the combination accelerates tendon, ligament or post-surgical recovery.
Class
Combination blend — synthetic pentadecapeptide (BPC-157) plus thymosin beta-4 fragment/protein (TB-500)
Half-life
Component-dependent: BPC-157 ~4 hours; TB-500 ~2–3 hours. No validated pharmacokinetic package exists for the blend.
Routes
Subcutaneous, Intramuscular, Local injection
Category
Healing & Recovery
Researched benefits
What it's studied for
Accelerated tissue healing
Marketed to speed repair of soft-tissue injuries by combining BPC-157's angiogenic, growth-factor effects with TB-500's actin-driven cell migration. Each component has real preclinical support, but the blend itself has no controlled human tendon or ligament trial.
Complementary repair mechanisms
The rationale is that the blend splits the repair job into two pathways — BPC-157 around nitric oxide signaling, angiogenesis and local growth-factor signaling, and TB-500 around actin regulation and cell migration. Complementary coverage is plausible; proven clinical synergy is not established.
Anti-inflammatory synergy
BPC-157 is well-studied in anti-inflammatory and local tissue models, and the pairing is promoted for reducing inflammation during recovery. Evidence is preclinical for the components and anecdotal for the combination.
Reduced recovery time in overuse injuries
Community and clinic reports cluster around tendinopathies and overuse injuries — rotator cuff, achilles, lateral epicondylitis, plantar fasciitis and MCL strains. Reports are consistent enough to matter as signal but are uncontrolled and subject to severe self-selection bias.
Single-injection convenience
One pre-blended vial replaces dosing two separate peptides, which is the most honest part of the case for a blend. There is no head-to-head data showing the blend outperforms either component dosed alone.
Mechanism
How it works
The blend combines BPC-157 and a component sold as TB-500 in a single vial, commonly around a 10 mg / 10 mg ratio. BPC-157 is a 15-amino-acid pentadecapeptide derived from a gastric-juice protective protein, studied mostly in localized wound, tendon and anti-inflammatory models. Its proposed actions center on nitric oxide signaling, angiogenesis (new blood-vessel formation) and growth-factor signaling that support local tissue repair.
The TB-500 side borrows from thymosin beta-4 biology: actin regulation and cell migration that drive wound-model repair. Labeling of the TB-500 component is inconsistent — some products contain the short LKKTETQ-related ~889 Da fragment while others contain the full 43-amino-acid thymosin beta-4 protein at ~4963 Da, so the certificate-of-analysis mass is the tell for what is actually in the vial.
On paper the two peptides cover different ground: BPC-157 acts as the more local, angiogenic component and TB-500 as the more systemic, cell-migration component. This makes for a mechanistically coherent stack, but coherence of mechanism is not proof that one vial changes human tendon, ligament or post-surgical outcomes. The combination was assembled outside the clinical-trial system, which is why the blend-specific evidence remains thinner than the marketing.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Supplied as lyophilized powder in 5 mg or 10 mg vials; reconstitute with bacteriostatic water per vendor instructions. Because component ratios and TB-500 identity vary between products, verify the certificate of analysis before dosing.
Beginner
- Dose
- Pre-blended vial per vendor instructions (typically BPC-157 250–500 mcg + TB-500 750–2500 mcg per injection)
- Frequency
- Once daily
- Timing
- Consistent time each day
- Duration
- 4 weeks
- Route
- Subcutaneous
Entry-level loading approach using a single pre-blended vial at the manufacturer's fixed ratio.
Intermediate
- Dose
- One pre-blended injection per dose
- Frequency
- Twice daily
- Timing
- Morning and evening during active injury recovery
- Duration
- 6 weeks
- Route
- Subcutaneous
Higher daily exposure aimed at an active recovery window.
Advanced
- Dose
- One pre-blended injection per dose
- Frequency
- 2 injections daily during loading, then once daily for maintenance
- Timing
- Split through the day
- Duration
- 4 weeks loading, then 4 weeks maintenance
- Route
- Subcutaneous
Loading-then-maintenance structure; GHK-Cu is sometimes added for skin/surface repair.
- Typical dose range: BPC-157 250–500 mcg plus TB-500 750–2500 mcg per injection, generally pre-blended at a fixed ratio.
- Loading phase runs once or twice daily for 4–8 weeks; maintenance is often reduced to about 3x per week as needed.
- Both local (near the injury site) and systemic subcutaneous or intramuscular routes appear in community and clinic practice, but no evidence-based route, dose or risk profile has been established for the blend.
- There is no FDA-approved administration protocol; route and dose claims vary widely across vendors, forums and clinics.
Evidence
Research & clinical studies (3)
No controlled clinical trials on the combined BPC-157 + TB-500 blend
No published RCTs exist on the finished blend; the case rests on component preclinical data plus uncontrolled practitioner and community reports (0 PubMed studies on the combination).
BPC-157 preclinical tendon and junctional repair literature
BPC-157 shows strong animal tendon and tendon-to-bone junctional repair data across more than 200 mostly preclinical papers, underpinning the blend's healing rationale.
Thymosin beta-4 / TB-500 wound and cell-migration studies
Approximately 50 preclinical thymosin beta-4/TB-500 studies support actin regulation, cell migration and wound-model repair, with limited human data drawn from cardiac-repair research.
Combinations
Stacking & blends
Triple Healing Stack
Combine deep-tissue repair with surface/skin healing
BPC/TB addresses deep tissue while GHK-Cu adds surface and skin repair — a synergistic combination noted in practitioner reports.
GLOW Blend
Broad tissue and skin recovery
GLOW pairs the BPC+TB repair base with GHK-Cu, dropping KPV, for a skin-and-tissue oriented blend.
KLOW Blend
Maximal multi-pathway healing and anti-inflammatory coverage
KLOW extends the BPC+TB base with both GHK-Cu and KPV to add copper-peptide skin repair and anti-inflammatory action.
Recovery + GH Support
Pair tissue healing with growth-hormone support
MK-677 (a GH secretagogue) is considered compatible, with GH support complementing the tissue-healing peptides during recovery.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Active cancer
- Pregnancy or breastfeeding
- Known hypersensitivity to either compound
- Competitive athletes subject to WADA testing (both peptides are prohibited)
Community reports are usually mild, with injection-site soreness the most common complaint, but that is not the same as a characterized safety profile. Blend-specific human trials have not formally mapped adverse events, product identity, sterility, route-specific risk or long-term outcomes.
FAQ
BPC-157 + TB-500 Blend — common questions
What is the BPC-157 / TB-500 blend?
A combination of two healing peptides in a single vial: BPC-157 (derived from a gastric-juice protective protein) and TB-500 (a thymosin beta-4 fragment, though vials often contain the full 43-amino-acid protein — the certificate-of-analysis mass tells you which). It is commonly stacked for tissue repair and injury recovery and is nicknamed the "wolverine stack."
What does the blend do?
It combines two mechanistic stories: BPC-157 is most studied in localized wound, tendon and anti-inflammatory models, while the TB-500 component points toward actin regulation and cell migration. Community users report faster recovery, but controlled human data on the combination does not exist.
How is it typically administered?
Most use is injection-based, subcutaneous or intramuscular, either near the injury site or systemically. Route and dose claims vary widely across forums, clinics and vendors, and there is no FDA-approved administration protocol for the blend.
What are the side effects?
Community reports are usually mild, with injection-site soreness the most common theme, plus occasional nausea, headache or temporary fatigue. Blend-specific trials have not formally mapped adverse events, product identity, sterility, route risk or long-term outcomes.
Is the blend FDA approved?
No. Both components are research chemicals and the blend has no FDA approval. Both peptides are also prohibited under WADA for competitive athletes.
Is the blend better than using the components separately?
The mechanisms are complementary and one vial is more convenient than two, which is the honest part of the case. However, there is no head-to-head data showing the blend outperforms either BPC-157 or TB-500 dosed alone.
Can it replace surgery?
No. Some soft-tissue injuries such as partial tears or tendinopathies may respond well enough that surgery becomes unnecessary, but structural injuries that require surgical intervention still require it. Framing the blend as a surgery replacement is marketing overreach.
